Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | TYMS | P04818 | 5/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Fluorodeoxyuridylate SCHEMBL6107 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL17117772 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL21901970 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15189164 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5491971 | 0.93 | LMNA (0.67) | LMNASMN1; SMN2TYMS | |
| SCHEMBL13026822 | 0.93 | LMNA (0.67) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15671694 | 0.92 | TYMS (0.64) | LMNASMN1; SMN2TYMS | |
| SCHEMBL28378385 | 0.92 | LMNA (0.66) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL25223991 | 0.91 | LMNA (0.69) | LMNASMN1; SMN2TYMS | |
| SCHEMBL5491976 | 0.91 | LMNA (0.69) | LMNASMN1; SMN2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935331-B1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-14 | — | — | US | claimed |
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250186435-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATIONS FOR TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2025-06-12 | — | — | US | disclosed |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250121087-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | INTOCELL, INC. (KR) | 2025-04-17 | — | — | US | disclosed |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | INTOCELL, INC. (KR) | 2024-12-17 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2023-12-21 | — | — | US | disclosed |
| WO-1998026786-A1 | CAGED MEMBRANE-PERMEANT INOSITOL PHOSPHATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-06-25 | — | — | WO | disclosed |
| US-5760022-A | ESTER, ETHER | PERSTORP AB (SE) | 1998-06-02 | — | — | US | disclosed |
| EP-0842181-A1 | MEMBRANE-PERMEANT SECOND MESSENGERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5693521-A | USING ACETOXYALKYL ESTER OF ADENOSINE(OR GUANOSINE)-3',5'-CYCLIC MONNOPHOSPHATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-12-02 | — | — | US | disclosed |
| US-5614510-A | AMMONIUM SALTS | PERSTORP AB (SE) | 1997-03-25 | — | — | US | disclosed |
| WO-1996040695-A1 | MEMBRANE-PERMEANT SECOND MESSENGERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0627922-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1994-12-14 | — | — | EP | disclosed |
| WO-1994023724-A1 | MEMBRANE-PERMEANT SECOND MESSENGERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1993016705-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | PRLHR, LHCGR, FCGR2A | LMNA 4140/4885SMN1; SMN2 4100/4885TYMS 4342/4885 |
| US-20250121087-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | CD274, CD44, H1-3 | LMNA 3972/4885SMN1; SMN2 3166/4885TYMS 2954/4885 |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | FCGR2A, FCGR3B, FCGR1A | LMNA 456/4885SMN1; SMN2 3041/4885TYMS 2903/4885 |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | LMNA 3724/4885SMN1; SMN2 2658/4885TYMS 1060/4885 |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | CD274, CD44, H1-3 | LMNA 3972/4885SMN1; SMN2 3166/4885TYMS 2954/4885 |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | LMNA 3724/4885SMN1; SMN2 2658/4885TYMS 1060/4885 |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LMNA 4745/4885SMN1; SMN2 4687/4885TYMS 1744/4885 |
| US-20250186435-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATIONS FOR TREATMENT OF CANCER | SLC5A1, DPYD, SLC46A1 | LMNA 4234/4885SMN1; SMN2 1316/4885TYMS 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.